Our results demonstrated that primary G-CSF prophylaxis reduced hematologic AEs (e.g., neutropenia and febrile neutropenia), and that an increase in dose intensity and treatment duration of FOLFIRINOX conferred a survival benefit in MPC patients. The gene discussed is CSF3; the disease is neutropenia.